Neurocrine Biosciences Inc (NAS:NBIX)
$ 142 3.52 (2.54%) Market Cap: 14.29 Bil Enterprise Value: 13.24 Bil PE Ratio: 39.12 PB Ratio: 5.99 GF Score: 89/100

Neurocrine Biosciences Inc at Cowen Health Care Conference Transcript

Mar 12, 2019 / 02:00PM GMT
Release Date Price: $80.97 (+1.19%)
Philip M. Nadeau
Cowen and Company, LLC, Research Division - MD and Senior Research Analyst

Good morning, and welcome once again to Cowen and Company's 39th Annual Health Care Conference. I'm Phil Nadeau, one of the biotech analysts here at Cowen and Company, and it's my pleasure to have a fireside chat with our next company, Neurocrine. We're really happy to have with us today Kevin Gorman, CEO, and Matt Abernethy, CFO. We'll do about 30 minutes in this room and then there is no breakout following.

Questions & Answers

Philip M. Nadeau
Cowen and Company, LLC, Research Division - MD and Senior Research Analyst

Kevin, maybe we'll start with you. Before we jump into this morning's data, could you give us a brief state-of-the-company overview? Where is Neurocrine in its long history and what you think needs to happen to drive outperformance over the next year or 2?

Kevin C. Gorman
Neurocrine Biosciences, Inc. - CEO & Director

Sure, Phil. To start out, thank you very much for the invitation, and thank

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot